Threshold effects in genetic toxicity: perspective of chemicals regulation in Germany.
In the regulation of chemical substances, it is generally agreed that there are no thresholds for genotoxic effects of chemicals, i.e. , that there are no doses without genotoxic effects. When classifying and labelling chemicals, dangerous properties of chemicals are to be identified. In this context, in general, the mode of action (threshold or not) is not considered for genotoxic substances. In the process of quantitative risk assessment, however, determination of the type of dose-effect relationships is decisive for the outcome and the type of risk management. The presence of a threshold must be justified specifically in each individual case. Inter alia, the following aspects may be discussed in this respect: aneugenic activity, indirect modes of action, extremely steep dose-effect relationships in combination with strong toxicity, specific toxicokinetic conditions which may lead to 'metabolic protection' prior to an attack of DNA. In the practice of the regulation of chemical substances with respect to their genotoxic effects, the discussion of thresholds has played a minor role. For notified new substances, there are, in general, no data available that would allow a reasonable discussion. Concerning substances out of the European programme on existing substances, so far 29 have been assessed in our institute with respect to genetic toxicity. Eight out of these have shown considerable evidence for genotoxicity. For two of them, a possible threshold is discussed: one substance is an aneugen, the other one is metabolised to an endogenic compound with genotoxic potential. In the practice of risk assessment of genotoxic substances, the discussion of the mode of action for genotoxicity is frequently associated with the evaluation of potential carcinogenic effects. Here, tissue-specific genotoxic effects in target organs for carcinogenicity are to be discussed. Moreover, the contribution of genotoxicity to the multifactorial process of tumour development should be assessed.
Madle
S
S
Federal Institute for Health Protection of Consumers and Veterinary Medicine (BgVV), Postfach 330013, D-14191, Berlin, Germany. s.madle@bgvv.de
von der Hude
W
W
Broschinski
L
L
Jänig
G
G
D004305:Dose-Response Relationship, Drug; D005069:Evaluation Studies as Topic; D005858:Germany; D009152:Mutagenicity Tests; D009153:Mutagens / Q000145:classification / Q000633:toxicity*; D018570:Risk Assessment / Q000331:legislation & jurisprudence; D014116:Toxicology / Q000331:legislation & jurisprudence
D009153:Mutagens